Drugs / RAD011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05387798 | Jan 2023 → Aug 2025 | Prader-Willi syndrome | Radius Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05098509 Comparator | Apr → Oct 2022 | Prader-Willi syndrome | Radius Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAD011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098509 ↗ |
| Route | Oral | “Participants were administered 40 mg/kg of RAD011 orally daily with food.” NCT05098509 ↗ |